Uma Kavita PhD

Uma Kavita received a B.S. in Microbiology from the Ohio State University, a Ph.D. in Microbiology and Immunology from Wake Forest University, and her post-doctoral training in Cellular Immunology (NKT cells) from Princeton University. Uma Kavita has worked for more than 17 years in biotech and biopharma in widely diverse research and development capacities. Uma Kavita has done proof-of-concept studies and developed whole genome amplification kits, identified and validated passive immunotherapy targets for cancer, conceptualized and solved recombinant influenza vaccine design issues using homology modeling, and developed novel and quick assays to identify structurally and functionally sound recombinant influenza vaccine candidates. Uma Kavita has led groups that developed and validated ELISAs and did sample analysis in clinical trials.

In her current role as Principal scientist in the bioanalytical science department at BMS, Uma Kavita leads the method development of PK and Immunogenicity assays for various new drug modalities (domain antibodies, anti-sense oligonucleotides, and viral or lipid nanoparticle-based gene therapeutics) and represent her team in cross-functional collaborations with Pharmacology, Regulatory, CMC, and Toxicology. Going forward, Uma Kavita would like to apply her diverse technical and theoretical expertise in the bioanalytical arena and participate in conversations related to regulatory issues.